CN107375194A - A kind of drug percutaneous penetrating agent and its application process - Google Patents
A kind of drug percutaneous penetrating agent and its application process Download PDFInfo
- Publication number
- CN107375194A CN107375194A CN201710510142.6A CN201710510142A CN107375194A CN 107375194 A CN107375194 A CN 107375194A CN 201710510142 A CN201710510142 A CN 201710510142A CN 107375194 A CN107375194 A CN 107375194A
- Authority
- CN
- China
- Prior art keywords
- penetrating agent
- drug
- medicine
- percutaneous penetrating
- drug percutaneous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 57
- 229940079593 drug Drugs 0.000 title claims abstract description 40
- 239000003795 chemical substances by application Substances 0.000 title claims abstract description 39
- 230000000149 penetrating effect Effects 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 10
- 230000008569 process Effects 0.000 title claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000019441 ethanol Nutrition 0.000 claims abstract description 14
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 13
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 13
- 241000723346 Cinnamomum camphora Species 0.000 claims abstract description 11
- 229930008380 camphor Natural products 0.000 claims abstract description 11
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 10
- 235000011187 glycerol Nutrition 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 7
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 7
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 claims abstract description 7
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 7
- 229940116229 borneol Drugs 0.000 claims abstract description 7
- 229960000846 camphor Drugs 0.000 claims abstract description 7
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000000839 emulsion Substances 0.000 claims abstract description 7
- 125000005909 ethyl alcohol group Chemical group 0.000 claims abstract description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 20
- 235000012000 cholesterol Nutrition 0.000 claims description 10
- 239000007762 w/o emulsion Substances 0.000 claims description 10
- 229960004756 ethanol Drugs 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 5
- 238000009792 diffusion process Methods 0.000 abstract description 4
- 238000011200 topical administration Methods 0.000 abstract description 4
- 150000002632 lipids Chemical class 0.000 abstract description 3
- 230000007246 mechanism Effects 0.000 abstract description 3
- 230000001225 therapeutic effect Effects 0.000 abstract description 3
- 230000009471 action Effects 0.000 abstract description 2
- 238000005267 amalgamation Methods 0.000 abstract description 2
- 238000005260 corrosion Methods 0.000 abstract description 2
- 230000007797 corrosion Effects 0.000 abstract description 2
- 238000004090 dissolution Methods 0.000 abstract description 2
- 239000011159 matrix material Substances 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 238000003756 stirring Methods 0.000 description 8
- 239000003921 oil Substances 0.000 description 5
- 150000001637 borneol derivatives Chemical class 0.000 description 4
- 239000005457 ice water Substances 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 239000003643 water by type Substances 0.000 description 4
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a kind of drug percutaneous penetrating agent and its application process, belong to topical administration technical field.The present invention includes 1 ~ 3 part of borneol, 1 ~ 3 part of camphor, 60 ~ 65 parts of absolute ethyl alcohols, 20 ~ 30 parts of water-in-oil emulsions, 1 ~ 2 part of sodium carboxymethylcellulose, 15 ~ 30 parts of glycerine, the present invention promotes the Transdermal absorption of medicine using the amalgamation of lipid film and skin, and strengthen the mobility of horn cell using the high-volume fractional ethanol contained, the design feature of the vesica shape of itself is utilized simultaneously, double action by medicine from the dissolution mechanism in matrix by diffusion transformation for corrosion and diffusion, deformation infiltrates into deep skin, it is effectively increased the transdermal amount of medicine, drug percutaneous penetrating agent of the present invention can be effectively improved the fat-soluble of medicine simultaneously, improve drug absorption rate, and improve therapeutic effect, have broad application prospects.
Description
Technical field
The present invention relates to a kind of drug percutaneous penetrating agent and its application process, belong to topical administration technical field.
Background technology
The skin organ maximum as human body is internal and an extraneous barrier system, and it is utilized in keratoderma
The multiple dense non-crystal structure of horn cell and intercellular lipid composition, it is rich in the very high protein of the degree of cross linking.Adjacent angular
Matter forms iuntercellular and closely connected by plasma membrane, by special transmembrane protein, pairing crosslinking each other, forms close connection knot
Structure, the influence of extraneous factor is prevented, form the main barrier of Drug Percutaneous Absorption, because the natural cover for defense of skin acts on, medicine
Percutaneous mechanism and unobvious.
Simultaneously because the fat-soluble difference of some drugs, is not easy to be directed through biomembrane, oral administration bioavilability is very low, shadow
The performance of drug effect has been rung, therefore has been drug administration carrier by selecting the drug percutaneous penetrating agent of high osmosis, has been increased by topical administration
Dosing thing is in joint part concentration, to improve therapeutic effect.During topical administration, percutaneous permeability is to influence drug effect to play
Key factor, medicine only penetrate into the blood vessel of skin corium and lymph and can be just absorbed by the body.Therefore, ground for percutaneous penetrating agent
Study carefully and be particularly important.
The content of the invention
The technical problems to be solved by the invention：For the natural cover for defense effect due to skin, the percutaneous rush of medicine oozes effect
The unconspicuous problem of fruit, the invention provides a kind of drug percutaneous penetrating agent and its application process.
In order to solve the above technical problems, the technical solution adopted by the present invention is：
A kind of drug percutaneous penetrating agent, including borneol, camphor, ethanol, water-in-oil emulsion, sodium carboxymethylcellulose, glycerine,
Characterized in that, the water-in-oil emulsion is the diethyl ether solution of phosphatide and cholesterol, it is evaporated under reduced pressure at room temperature to gel
It is made.
The borneol, camphor, ethanol, water-in-oil emulsion, sodium carboxymethylcellulose, the parts by weight of glycerine are 1 ~ 3 part
Borneol, 1 ~ 3 part of camphor, 60 ~ 65 parts of absolute ethyl alcohols, 20 ~ 30 parts of water-in-oil emulsions, 1 ~ 2 part of sodium carboxymethylcellulose, 15 ~ 30
Part glycerine.
The quality of the cholesterol diethyl ether solution is 2.5 ~ 10 times of phosphatide.
The mass fraction of the cholesterol diethyl ether solution is 5 ~ 10%.
The sodium carboxymethylcellulose is to be swelled to be made at 70 ~ 80 DEG C through deionized water.
A kind of application process of described drug percutaneous penetrating agent is to be passed through after medicine is dissolved in absolute ethyl alcohol with medicine
Agents area can be coated in after skin penetrating agent is well mixed.
In a kind of application process of described drug percutaneous penetrating agent drug dose for drug percutaneous penetrating agent quality 10 ~
20%。
The method have the benefit that：
（1）The present invention promotes the Transdermal absorption of medicine using the amalgamation of lipid film and skin, and utilizes the high volume integral contained
Number ethanol strengthens the mobility of horn cell, while using the design feature of the vesica shape of itself, by medicine from matrix
Dissolution mechanism is infiltrated into deep skin, is effectively increased the saturating of medicine by the double action that diffusion transformation is corrosion and diffusion, deformation
Pi Liang.
（2）Drug percutaneous penetrating agent of the present invention can be effectively improved the fat-soluble of medicine, improve drug absorption rate, and improve and control
Therapeutic effect, have broad application prospects.
Embodiment
Take 10 ~ 20g phosphatide, adding 50 ~ 100g mass fractions is in 10% cholesterol diethyl ether solution, in ice-water bath with
300W ultrasonic echographies disperse 20 ~ 30min, then are evaporated under reduced pressure at room temperature to gel, obtain water-in-oil emulsion, take 1 ~ 2g carboxylics
Sodium carboxymethylcellulose pyce is added in 20 ~ 40mL deionized waters, and 40 ~ 50min is swelled at 70 ~ 80 DEG C, adds 20 ~ 30g Water-In-Oils
Type emulsion, 1 ~ 3g borneols, 1 ~ 3g camphors, 60 ~ 65g absolute ethyl alcohol, 20 ~ 30min is stirred with 300 ~ 400r/min, obtains mixed liquor,
Mixed liquor and 15 ~ 30g glycerine are added 1 ~ 2h is ground in grinder, brown bottle sealing is placed in after discharging, is protected at 0 ~ 4 DEG C
Deposit, obtain drug percutaneous penetrating agent, take 1 ~ 2g medicines add 10 ~ 20mL absolute ethyl alcohols in, with 300 ~ 400r/min stirring 20 ~
30min, 10 ~ 20g drug percutaneous penetrating agents are added, agents area is coated in after continuing 10 ~ 15min of stirring.
Example 1
10g phosphatide is taken, it is in 10% cholesterol diethyl ether solution, with 300W ultrasonic echographies in ice-water bath to add 50g mass fractions
Scattered 20min, then be evaporated under reduced pressure at room temperature to gel, water-in-oil emulsion is obtained, takes 1g sodium carboxymethylcelluloses to add
In 20mL deionized waters, 40min is swelled at 70 DEG C, adds 20g water-in-oil emulsions, 1g borneols, 1g camphors, 60g is anhydrous
Ethanol, 20min is stirred with 300r/min, obtains mixed liquor, mixed liquor and 15g glycerine are added in grinder and grind 1h, is discharged
After be placed in brown bottle sealing, preserved at 0 DEG C, obtain drug percutaneous penetrating agent, take 1g medicines add 10mL absolute ethyl alcohols in, with
300r/min stirs 20min, adds 10g drug percutaneous penetrating agents, continues to be coated in agents area after stirring 10min.
Example 2
15g phosphatide is taken, it is in 10% cholesterol diethyl ether solution, with 300W ultrasonic echographies in ice-water bath to add 75g mass fractions
Scattered 25min, then be evaporated under reduced pressure at room temperature to gel, water-in-oil emulsion is obtained, takes 1.5g sodium carboxymethylcelluloses to add
In 30mL deionized waters, 45min is swelled at 75 DEG C, adds 25g water-in-oil emulsions, 2g borneols, 2g camphors, 63g is anhydrous
Ethanol, 25min is stirred with 350r/min, obtains mixed liquor, mixed liquor and 20g glycerine are added in grinder and grind 1h, is discharged
After be placed in brown bottle sealing, preserved at 2 DEG C, obtain drug percutaneous penetrating agent, take 1.5g medicines add 15mL absolute ethyl alcohols in, with
300r/min stirs 25min, adds 15g drug percutaneous penetrating agents, continues to be coated in agents area after stirring 12min.
Example 3
20g phosphatide is taken, it is in 10% cholesterol diethyl ether solution to add 100g mass fractions, is surpassed in ice-water bath with 300W ultrasonic waves
Sound disperses 30min, then is evaporated under reduced pressure at room temperature to gel, obtains water-in-oil emulsion, takes 2g sodium carboxymethylcelluloses to add
In 40mL deionized waters, 50min is swelled at 80 DEG C, adds 30g water-in-oil emulsions, 3g borneols, 3g camphors, 65g is anhydrous
Ethanol, 30min is stirred with 400r/min, obtains mixed liquor, mixed liquor and 30g glycerine are added in grinder and grind 2h, is discharged
After be placed in brown bottle sealing, preserved at 4 DEG C, obtain drug percutaneous penetrating agent, take 2g medicines add 20mL absolute ethyl alcohols in, with
400r/min stirs 30min, adds 20g drug percutaneous penetrating agents, continues to be coated in agents area after stirring 15min.
Comparative example：Absolute ethyl alcohol
The permeability and infiltration capacity of each drug percutaneous penetrating agent of table 1
| Detection project | Example 1 | Example 2 | Example 3 | Comparative example |
| Infiltration rate/（μg·cm-2·h） | 15.434 | 17.485 | 19.539 | 11.187 |
| Accumulation infiltration capacity/（μg·cm-2） | 361.347 | 379.577 | 413.248 | 212.149 |
| Permeability % | 17.89 | 18.73 | 20.48 | 13.41 |
As can be seen from the above table, drug percutaneous penetrating agent produced by the present invention can be effectively increased the transdermal amount of medicine, promote medicine
Absorb, have broad application prospects.
Claims (7)
1. a kind of drug percutaneous penetrating agent, including borneol, camphor, ethanol, water-in-oil emulsion, sodium carboxymethylcellulose, the third three
Alcohol, it is characterised in that the water-in-oil emulsion is the diethyl ether solution of phosphatide and cholesterol, is evaporated under reduced pressure at room temperature to gel
Shape is made.
2. a kind of drug percutaneous penetrating agent as claimed in claim 1, it is characterised in that borneol, camphor, ethanol, water-in-oil type
Emulsion, sodium carboxymethylcellulose, the parts by weight of glycerine are 1 ~ 3 part of borneol, 1 ~ 3 part of camphor, 60 ~ 65 parts of absolute ethyl alcohols, 20 ~ 30
Part water-in-oil emulsion, 1 ~ 2 part of sodium carboxymethylcellulose, 15 ~ 30 parts of glycerine.
A kind of 3. drug percutaneous penetrating agent as claimed in claim 1, it is characterised in that the quality of the cholesterol diethyl ether solution
For 2.5 ~ 10 times of phosphatide.
A kind of 4. drug percutaneous penetrating agent as claimed in claim 1, it is characterised in that the quality of the cholesterol diethyl ether solution
Fraction is 5 ~ 10%.
5. a kind of drug percutaneous penetrating agent as claimed in claim 1, it is characterised in that the sodium carboxymethylcellulose is through going
Ionized water is swelled at 70 ~ 80 DEG C to be made.
6. the application process of a kind of drug percutaneous penetrating agent as described in any one of claim 1 ~ 5, it is characterised in that described to answer
With for by medicine be dissolved in absolute ethyl alcohol after be well mixed with drug percutaneous penetrating agent after can be coated in agents area.
7. a kind of application process of drug percutaneous penetrating agent as claimed in claim 5, it is characterised in that drug dose is medicine
The 10 ~ 20% of percutaneous penetrating agent quality.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710510142.6A CN107375194A (en) | 2017-06-28 | 2017-06-28 | A kind of drug percutaneous penetrating agent and its application process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710510142.6A CN107375194A (en) | 2017-06-28 | 2017-06-28 | A kind of drug percutaneous penetrating agent and its application process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107375194A true CN107375194A (en) | 2017-11-24 |
Family
ID=60334396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710510142.6A Pending CN107375194A (en) | 2017-06-28 | 2017-06-28 | A kind of drug percutaneous penetrating agent and its application process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107375194A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030180367A1 (en) * | 1996-08-22 | 2003-09-25 | Skyepharma Canada, Inc. | Microparticles of water-insoluble substances |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| CN102552147A (en) * | 2011-02-11 | 2012-07-11 | 舒泰神（北京）生物制药股份有限公司 | Bullatacin ethosome gel and preparation method thereof |
| CN102579323A (en) * | 2011-02-21 | 2012-07-18 | 舒泰神（北京）生物制药股份有限公司 | Paclitaxel ethosome gel and preparation method thereof |
| CN105434337A (en) * | 2015-04-03 | 2016-03-30 | 武汉科福新药有限责任公司 | Propranolol hydrochloride submicron emulsion gel and preparation method and application thereof |
-
2017
- 2017-06-28 CN CN201710510142.6A patent/CN107375194A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030180367A1 (en) * | 1996-08-22 | 2003-09-25 | Skyepharma Canada, Inc. | Microparticles of water-insoluble substances |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| CN102552147A (en) * | 2011-02-11 | 2012-07-11 | 舒泰神（北京）生物制药股份有限公司 | Bullatacin ethosome gel and preparation method thereof |
| CN102579323A (en) * | 2011-02-21 | 2012-07-18 | 舒泰神（北京）生物制药股份有限公司 | Paclitaxel ethosome gel and preparation method thereof |
| CN105434337A (en) * | 2015-04-03 | 2016-03-30 | 武汉科福新药有限责任公司 | Propranolol hydrochloride submicron emulsion gel and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 杨义芳等主编: "《中药药效物质》", 30 April 2012, 上海科学技术出版社 * |
| 白洁等: "芍药苷凝胶剂与醇质体凝胶剂透皮性能比较", 《中国实验方剂学杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hosszu et al. | Sex differences in renal ischemia-reperfusion injury | |
| CN107375194A (en) | A kind of drug percutaneous penetrating agent and its application process | |
| CN103417937B (en) | Clean spray of Corallium Japonicum Kishinouye tinea and preparation method thereof | |
| CN101991585A (en) | Percutaneous absorption film coating agent for treating rheumatoid arthritis and preparation method thereof | |
| CN103006554A (en) | Ornidazole injection and preparation method thereof | |
| CN104721234A (en) | Periplaneta Americana extract product ion-activated in-situ gel and preparation method thereof | |
| CN101623286B (en) | Transdermal administration composite containing cucurbitacin-type active ingredient | |
| CN101375867B (en) | Oligosaccharide of mycelium of Hericium erinaceus extracted from fermentation product of mycelium of Hericium erinaceus and uses thereof | |
| CN105030671B (en) | Methimazole micro emulsion, methimazole micro emulsion gel and its preparation method and application | |
| CN102058613B (en) | The purposes of anti-tumor active ingredient compositions in Herba Solani Nigri | |
| CN107929265A (en) | Preparation method of medicinal transdermal material | |
| Lopes et al. | Evaluation of in vitro percutaneous enhancement effect of papain and pequi oil on diclofenac sodium permeation through human skin | |
| CN102670624B (en) | Patch for treating rheumatic arthritis and preparation method thereof | |
| CN105342986A (en) | Terbinafine hydrochloride gel and preparation method thereof | |
| CN100370982C (en) | Pulsatilla Transdermal Gel | |
| CN104225030B (en) | A kind of soak treating tinea manus and pedis sweaty feet with bromidrosis and preparation method thereof | |
| CN104257740A (en) | Preparation method of volatile oil of Chinese mosla herb and application in anti-inflammatory and analgesia of same | |
| CN105193726B (en) | A kind of medicinal composition for treating onychomycosis | |
| CN106038623A (en) | A preparing method for valeriana officinalis var. latifolia root volatile oil and inflammation-diminishing and pain-easing applications of the volatile oil | |
| CN104274494A (en) | America periplaneta external preparation and preparation method thereof | |
| CN103585102A (en) | Fosfluconazole venous transfusion administration preparation and preparation method thereof | |
| CN100443085C (en) | A kind of compound gel for external use and preparation method thereof | |
| CN105687198B (en) | A kind of rutaecarpin Transdermal absorption spray | |
| CN106166180A (en) | A kind of Chinese medicine composition treating oral ulcer and application thereof | |
| Yang et al. | Pharmacological Mechanism and Clinical Research Progress of Cordyceps Sinensis Preparations (Bailing Capsules) in the Treatment of Chronic Kidney Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171124 |